LivaNova PLC

Equities

LIVN

GB00BYMT0J19

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
54.01 ^USD	+3.21%		+1.20%	+4.39%

Mar. 20	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Mar. 20	Sector Update: Health Care Stocks Down Wednesday Afternoon	MT

LivaNova PLC Appoints Alex Shvartsburg as Chief Financial Officer, Effective August 1, 2021

July 28, 2021 at 06:03 am EDT

LivaNova PLC announced that it has appointed Alex Shvartsburg to the role of Chief Financial Officer (CFO) effective August 1, 2021. Shvartsburg has served as interim CFO of LivaNova since October 31, 2020 and brings over 25 years of relevant industry experience, serving in roles across global corporate finance, planning and analysis, mergers and acquisitions and treasury.

Latest news about LivaNova PLC

Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 20	MT
Sector Update: Health Care Stocks Down Wednesday Afternoon	Mar. 20	MT
LivaNova Says Sleep Apnea Study Likely to Meet Primary Efficacy Endpoint; Shares Jump	Mar. 20	MT
LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea	Mar. 20	CI
Transcript : LivaNova PLC Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	Mar. 12
LivaNova Proposes $300 Million Private Placement of Notes	Mar. 04	MT
Barclays Adjusts Price Target on LivaNova to $61 From $57, Keeps Equalweight Rating	Feb. 27	MT
Barclays Raises Price Target on LivaNova to $61 From $57, Maintains Equalweight Rating	Feb. 26	MT
Wolfe Research Adjusts LivaNova's Price Target to $65 From $58, Keeps Outperform Rating	Feb. 22	MT
Baird Adjusts LivaNova's Price Target to $62 From $56, Keeps Neutral Rating	Feb. 22	MT
Mizuho Securities Adjusts Price Target on LivaNova to $75 From $70, Maintains Buy Rating	Feb. 22	MT
Needham Adjusts Price Target on LivaNova to $72 From $62, Keeps Buy Rating	Feb. 21	MT
Transcript : LivaNova PLC, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
LivaNova's Q4 Adjusted Earnings, Revenue Increase; Sets 2024 Guidance	Feb. 21	MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 Revenue $310.1M, vs. Street Est of $287.7M	Feb. 21	MT
Earnings Flash (LIVN) LIVANOVA Reports Q4 EPS $0.87, vs. Street Est of $0.77	Feb. 21	MT
LivaNova PLC Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Livanova plc Provides Earnings Guidance for the Full-Year 2024	Feb. 21	CI
LivaNova PLC Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023	Feb. 21	CI
Mizuho Securities Upgrades LivaNova to Buy From Neutral, Raises Price Target to $70 From $60	Feb. 20	MT
LivaNova Names Vladimir Makatsaria as Chief Executive	Feb. 05	MT
FTSE 100 Closes Down 0.03% After US Data Hit Rate-Cut Hopes	Feb. 05	DJ
LivaNova PLC Announces Board Changes, Effective on March 1, 2024	Feb. 05	CI
LivaNova PLC Announces CEO Changes, Effective on March 1, 2024	Feb. 05	CI

Chart LivaNova PLC

Duration

Period

More charts

Company Profile

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Companyâs next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for LivaNova PLC

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

54.01 USD

Average target price

66.1 USD

Spread / Average Target

+22.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
LIVANOVA PLC	+4.39%	2.91B
ABBOTT LABORATORIES	-2.73%	186B
MEDTRONIC PLC	-2.20%	107B
BECTON, DICKINSON AND COMPANY	-4.08%	67.57B
DEXCOM, INC.	+5.99%	50.7B
CENCORA, INC.	+15.32%	47.2B
HOYA CORPORATION	-0.51%	39.72B
WEST PHARMACEUTICAL SERVICES, INC.	+6.60%	27.48B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.11%	25.65B
ZIMMER BIOMET HOLDINGS, INC.	-0.76%	24.82B

Other Medical Equipment, Supplies & Distribution